Table of Contents
Table of Contents 2

Introduction 7
Global Markets Direct Report Coverage 7
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Overview 8
Therapeutics Development 9
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Stage of Development 9
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Therapy Area 10
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Indication 11
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Companies 15
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Universities/Institutes 18
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Companies Involved in Therapeutics Development 27
BioMAS Ltd. 27
Biotest AG 28
enGene, Inc 29
Intrexon Corporation 30
LEO Pharma A/S 31
Merck & Co., Inc. 32
P2D Bioscience 33
Pfizer Inc. 34
SK Biopharmaceuticals Co., Ltd. 35
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Drug Profiles 36
AM-0010 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ANV-103 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
AS-101 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 Diabetes - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Biologic to Target Gluten and IL-10 for Celiac Disease - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Biologic to Target Insulin Receptor and IL-10 for Type 1 Diabetes - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
BT-063 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Dekavil - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
EG-10 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
EG-12 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Elmyelin - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Gene Therapy to Activate Interleukin-10 for ALS - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
LEO-32731 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
MK-1966 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
PD-2244 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
SKL-16036 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Synthetic Peptides to Inhibit IL-10 and IFN Gamma for Cancer, Viral Infections and Inflammatory Diseases - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
XT-101 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
XT-150 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Dormant Projects 61
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Discontinued Products 64
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Featured News & Press Releases 65
Jun 06, 2016: ARMO BioSciences AM0010 Demonstrates Promising Clinical Data as an Immuno-oncology Monotherapy and in Combination with an Anti-PD-1 Checkpoint Inhibitor in Advanced Solid Tumors, Including Immune-Resistant Cancers 65
Apr 20, 2016: ARMO BioSciences Announces AM0010 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting in June 2016 66
Mar 31, 2016: Xalud Therapeutics Discovers Potential Solution for Opioid Abuse Crisis 67
Mar 16, 2016: ARMO BioSciences to Present New Clinical Trial Results for AM0010 at Upcoming Medical Conferences 68
Jan 08, 2016: ARMO BioSciences to Present at the 34th Annual J.P. Morgan HealthCare Conference 68
Oct 30, 2015: ARMO BioSciences Presents Positive Phase 1 Trial Results of AM0010 at Upcoming Medical Conferences 69
Oct 06, 2015: Biotest reaches the next milestone in the clinical development of its monoclonal antibody BT-063 by starting the clinical phase IIa trial in the indication systemic lupus erythematosus 69
Jun 01, 2015: ARMO BioSciences Announces Efficacy and Safety Data for Immuno-Oncology Program with Novel Mechanism of Action 70
May 13, 2015: ARMO BioSciences Announces Presentation on Promising Immuno-Oncology Program at 2015 ASCO Annual Meeting 71
Jun 23, 2014: Cytovance Biologics selected for GMP manufacture of AM0010 for ARMO BioSciences 71
Nov 25, 2013: ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy 72
Apr 11, 2012: University Of Leuven And ActoGeniX Announce Study Results Of ActoBiotic In Treatment Of Type 1 Diabetes 72
Sep 30, 2009: Biotest AG Announces Initiation of Clinical development of BT-063 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75

List of Tables
Number of Products under Development for, H1 2016 9
Number of Products under Development by Therapy Area, H1 2016 10
Number of Products under Development by Indication, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Development by Companies, H1 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H1 2016 18
Products under Investigation by Universities/Institutes, H1 2016 19
Assessment by Monotherapy/Combination Products, H1 2016 20
Number of Products by Stage and Mechanism of Action, H1 2016 22
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 26
Pipeline by BioMAS Ltd., H1 2016 27
Pipeline by Biotest AG, H1 2016 28
Pipeline by enGene, Inc, H1 2016 29
Pipeline by Intrexon Corporation, H1 2016 30
Pipeline by LEO Pharma A/S, H1 2016 31
Pipeline by Merck & Co., Inc., H1 2016 32
Pipeline by P2D Bioscience, H1 2016 33
Pipeline by Pfizer Inc., H1 2016 34
Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 35
Dormant Projects, H1 2016 61
Dormant Projects (Contd..1), H1 2016 62
Dormant Projects (Contd..2), H1 2016 63
Discontinued Products, H1 2016 64

List of Figures
Number of Products under Development for, H1 2016 9
Number of Products under Development by Therapy Area, H1 2016 10
Number of Products under Development by Top 10 Indication, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy/Combination Products, H1 2016 20
Number of Products by Mechanism of Actions, H1 2016 21
Number of Products by Stage and Mechanism of Actions, H1 2016 21
Number of Products by Routes of Administration, H1 2016 23
Number of Products by Stage and Routes of Administration, H1 2016 23
Number of Products by Molecule Types, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 25

Companies Mentioned
BioMAS Ltd.
Biotest AG
enGene, Inc
Intrexon Corporation
LEO Pharma A/S
Merck & Co., Inc.
P2D Bioscience
Pfizer Inc.
SK Biopharmaceuticals Co., Ltd.